Concepedia

Kit Cheng

KC

Statistics

Publications

9

Citations

354

H-Index

9

Active since

1997

Affiliations

Hartford Financial Services (United States)(Current)

Massachusetts General Hospital

Lowell General Hospital

Memorial Sloan Kettering Cancer Center

St. Luke's Mountain States Tumor Institute

Kit Cheng is an author at Hartford Financial Services (United States) specializing in pharmacology, medicine, and oncology.

ORCID

Publications per year

1997–2024

9

Publications

9

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

Sara M. Tolaney, Nabihah Tayob, Chau T. Dang et al. · Journal of Clinical Oncology · 2021 · 139 citations · Full text

, , +14

Effect of Grapefruit Juice on Clarithromycin Pharmacokinetics

Kit Cheng, Anne N. Nafziger, Charles A. Peloquin et al. · Antimicrobial Agents and Chemotherapy · 1998 · 52 citations · Full text

, , +7

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT

Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa et al. · Journal of Clinical Oncology · 2024 · 38 citations · Full text

, , +17

Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)

Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob et al. · Breast Cancer Research and Treatment · 2021 · 37 citations

, , +12

Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)

Sara M. Tolaney, Lorenzo Trippa, William T. Barry et al. · Cancer Research · 2020 · 26 citations

, , +17

1–5 of 9